Evidence map›Paper›PMID 35419822›Full record

ArticleEuropean journal of immunology2022

Anti-IFN-α/-ω neutralizing antibodies from COVID-19 patients correlate with downregulation of IFN response and laboratory biomarkers of disease severity.

Federica Frasca, Mirko Scordio, Letizia Santinelli, Lucia Gabriele, Orietta Gandini, Anna Criniti, Alessandra Pierangeli, Antonio Angeloni, Claudio M Mastroianni, Gabriella d'Ettorre and 3 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed, 2 pooled it
5.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 2 syntheses or guidelines pooled it, 53 citations in OpenAlex.

  1. Pooled it
  2. Autoantibodies against type I interferons in COVID-19 infection: A systematic review and meta-analysis.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2023
    Pooled it
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Type I IFN autoantibodies underlie chikungunya live-attenuated vaccine encephalitis.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 2 countries.

Federica FrascaLaboratory of Microbiology and Virology, Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy.
Mirko ScordioLaboratory of Microbiology and Virology, Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy.
Letizia SantinelliLaboratory of Microbiology and Virology, Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy.
Lucia GabrieleDepartment of Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy.
Orietta GandiniDepartment of Molecular Medicine, Sapienza University of Rome, Rome, Italy.
Anna CrinitiDepartment of Experimental Medicine, Policlinico Umberto I, Sapienza University of Rome, Rome, Italy.
Alessandra PierangeliLaboratory of Microbiology and Virology, Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy.
Antonio AngeloniDepartment of Experimental Medicine, Policlinico Umberto I, Sapienza University of Rome, Rome, Italy.
Claudio M MastroianniDepartment of Public Health and Infectious Diseases, Policlinico Umberto I, Sapienza University of Rome, Rome, Italy.
Gabriella d'EttorreDepartment of Public Health and Infectious Diseases, Policlinico Umberto I, Sapienza University of Rome, Rome, Italy.
Raphael P ViscidiDepartment of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Guido AntonelliLaboratory of Microbiology and Virology, Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy.
Carolina ScagnolariLaboratory of Microbiology and Virology, Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy.ORCID 0000-0003-1044-1478
Sapienza University of Rome · ITPoliclinico Umberto I · ITIstituto Superiore di Sanità · ITJohns Hopkins University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A significant number of COVID-19 patients were shown to have neutralizing antibodies (NAB) against IFN; however, NAB specificity, fluctuation over time, associations with biochemical and hematological parameters, and IFN gene expression are not well characterized. Binding antibodies (BAB) to IFN-α/-β were screened in COVID-19 patients' serum. All BAB positive sera, and a subset of respiratory samples, were tested for NAB against IFN-α/-β/-ω, using an antiviral bioassay. Transcript levels of IFN-α/-β/-ω and IFN-stimulated genes (ISGs) were quantified. Anti-IFN-I BAB were found in 61 out of 360 (17%) of patients. Among BAB positive sera, 21.3% had a high NAB titer against IFN-α. A total of 69.2% of anti-IFN-α NAB sera displayed cross-reactivity to IFN-ω. Anti-IFN-I NAB persisted in all patients. NAB to IFN-α were also detected in 3 out of 17 (17.6%) of respiratory samples. Anti-IFN-I NAB were higher in males (p = 0.0017), patients admitted to the ICU (p < 0.0001), and patients with a fatal outcome (p < 0.0001). NAB were associated with higher levels of CRP, LDH, d-Dimer, and higher counts of hematological parameters. ISG-mRNAs were reduced in patients with persistently NAB titer. NAB are detected in a significant proportion of severe COVID-19. NAB positive patients presented a defective IFN response and increased levels of laboratory biomarkers of disease severity.

Indexed as

Antibodies, NeutralizingCOVID-19BiomarkersDown-RegulationHumansInterferon-alphaInterferon-betaMaleSeverity of Illness IndexAntibodies, NeutralizingBiomarkersInterferon-alphaInterferon-betaautoantibodies, SARS-CoV-2binding antibodiesCOVID-19InterferonISGneutralizing antibodies

Identifiers

PMID35419822
PMCPMC9087404
OpenAlexW4223968834

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.